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fort, psychosocial discomfort, worries/concerns, and satisfaction). For the overall
scale and each subscale of PAC-SYMandPAC-QOL, scores can range from0 through
4, higher scores indicate worse situation. RESULTS: Both placebo and prucalopride
groups were well-matched at baseline in terms of demographic data and disease
characteristics such as age, gender distribution, body weight, BMI, overall scales
and subscales of PAC-SYM and PAC-QOL. At week 12 last observation carried for-
ward (LOCF), the mean score reduction was significantly greater in the prucalo-
pride group than that in the placebo group for the overall PAC-SYMscore (0.3 point),
the stool symptom (0.4 point), the abdominal symptom (0.2 point) and the rectal
symptom (0.2 point) (P0.008). Mean overall PAC-QOL scores showed significant
improvement (0.3 point) with prucalopride than with placebo (at week 12 LOCF), as
well as physical discomfort (0.3 point), psychosocial discomfort (0.2 point), worries/
concerns (0.2 point), and satisfaction (0.6 point) (P0.017).CONCLUSIONS:During a
treatment period of 12 weeks, prucalopride significantly reduced the severity of
symptoms, and improved satisfaction and the disease-related quality of life in
Chinese patients with chronic constipation.
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OBJECTIVES: To investigate whether maternal exposure to topical corticosteroids
results in adverse pregnancy outcomes.METHODS:We used the UK Health Infor-
matics Centre (HIC) Datasets to conduct a population-based retrospective cohort
study. We identified 2645 women who were given a topical corticosteroid during
the period from last menstrual period (LMP) to delivery and 7212 unexposed
women matched for maternal age and the calendar year of pregnancy. We exam-
ined if there was an increased risk of adverse pregnancy outcomes (including oro-
facial cleft, low birth weight, preterm delivery, and stillbirth) in the exposed group.
RESULTS: No significant increase in adverse pregnancy outcomes (including oro-
facial cleft, low birth weight, preterm delivery, and stillbirth) was found in relation
to maternal exposure to topical corticosteroid [adjusted risk ratio (RR) 1.85 [95%
confidence interval (CI) 0.22-15.20], 0.97 (95% CI 0.78-1.19), 1.14 (95% CI 0.70-1.86),
and 1.04 (95% CI 0.55-1.98), respectively]. Stratified analyses based on the potency
of topical corticosteroids did not substantially change the results. Neither did sen-
sitivity analyses that included topical corticosteroids given up to 85 days before last
menstrual period. CONCLUSIONS: Congruent with previous studies, the present
study found no associations of maternal exposure to topical corticosteroids with
orofacial cleft, preterm delivery and stillbirth. In contrast to two previous cohort
studies, the present study did not find an association of low birth weight with
maternal exposure to either potent or very potent topical corticosteroid. This, how-
ever, may be due to the limited sample size and the risk being small.
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Twenty-five to 30 % of menopausal Indian women suffer from local vaginal symp-
toms. Dearth of Indian data on hormone therapy to relieve local vaginal symptoms
prompted this research. OBJECTIVES: The overall objective of the research was to
assess the effects of treatment with local estrogen therapy on atrophic vaginitis
and gynecological health in Indian postmenopausal women.METHODS:Data of 50
menopausal Indian women having moderate to severe vaginal atrophy was col-
lected. It was ensured that the women had intact uterus and were not suffering
from any significant uterine pathology. Vaginal maturation index (VMI), vaginal
pH, and severity of participant-reported most bothersome symptom (vaginal dry-
ness, itching, burning, or dyspareunia) at week 12 were the primary outcome.
Physiological changes were assessed by Genital Health Clinical Evaluation (GCHE)
tool. Local estrogen therapy in the form of Conjugated Equine Estrogen and Estra-
diol was used in the dose of 0.5 g twice a week and 1 mg daily respectively for 12
weeks RESULTS: At week 12, there was significant improvements in VMI with the two
low-dose preparations compared to baseline values (p0.05). Local estrogen therapy re-
duced the most bothersome symptoms in 80 % of the patients. There was a significant
improvement inGCHEscoreafter12weeks.The localestrogentherapywaswell tolerated
in the patients and the adverse events were noted in only 5% of the patients.
CONCLUSIONS: Local estrogen therapywaseffective in relieving the symptomsofmod-
erate-to-severe atrophic vaginitis when used twice weekly. Twelve weeks local estrogen
therapy was well tolerated and resulted in beneficial changes in the vaginal tissue and
inducedanoverall genitalhealthpatternmorecharacteristicof thepremenopausal state.
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OBJECTIVES: Serotonin reuptake inhibitors (SRIs) are extensively used in manage-
ment of clinical depression. Reports vary about the risk of these drugs during
pregnancy. To determine the risk of exposure to SRIs, we pooled data frommultiple
clinical studies that investigated obstetrical outcomes in women exposed to this
group of drugs during pregnancy. METHODS: Studies were identified by search of
PUBMED, OVID, Web of Sciences and SCOPUS databases and the data were derived
from 1966 to 2011(September). Types of outcome investigated were spontaneous
abortion, major malformations, cardiovascular malformations, and minor malfor-
mations. The criteria for inclusion of studies in this meta-analysis were exposure
of women to any therapeutic dosage of SRI (citalopram, fluoxetine, fluvoxamine,
paroxetine, sertraline, escitalopram, venlafaxine) during pregnancy. RESULTS: A
total of 22 studies and 616 522 patientswere included in themeta-analysis. Overall,
we did not find significant risks of cardiovascular and minor malformations for
exposure to SIRs during all trimesters of pregnancy but OR for spontaneous abor-
tion was 1.87 with 95% CI  1.5 to 2.33 and for major malformations 1.37 with 95%
CI  1.11 to 1.68 respectively. CONCLUSIONS: Our results find that SRIs do not
increase the risk of cardiovascular and minor malformations but increasing the
risks of spontaneous abortion and major malformations significantly should be
consider during pregnancy cautiously.
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OBJECTIVES: To evaluate immunization status and to identify the family factors
associatedwith immunization rate in children younger than two years.METHODS:
A cross-sectional and a cluster sampling design were implemented; five hundred
twenty eight representative Iraqi families with children between 18 and 70months
of age were interviewed in five public health clinics in Mosul-Iraq. Demographic
characteristics of the child and family, and the child’s immunization history were
obtained. Immunization rate or completeness for the following six vaccines were
assessed: one dose of Bacille Calmette-Guérin (BCG) vaccine; five doses of polio
(OPV); three doses of hepatitis B (HBV) vaccine; four doses of diphtheria, tetanus,
and pertussis (DTP) vaccine; one dose of measles, mumps, and rubella (MMR) vac-
cine; one dose of themeasles vaccine. Risk factors for partial immunization for the
1-5-3-4-1-1 vaccine series were explored using both bivariate analyses and multi-
level logistic regression models. RESULTS: More than half of the children were
immunized with all vaccination doses therefore considered as complete immuni-
zation cases. In addition, less than half of the children had one or more than one
missed dose, considered as partial immunization cases. The study found signifi-
cant associations of immunization completeness with father’s education level,
mother’s education level, mother’s race and family income. Six factors were found
that strongly impacted on immunization completeness in the presence of other
factors; birthplace, number of preschool children, family income, father’s educa-
tion, mother’s education and marital status. CONCLUSIONS: There is a need to in-
crease awareness and knowledge about the benefits and importance of vaccination, as
well as the harmful consequences of non-complete or partial immunization.
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OBJECTIVES: To obtain information on provider payment scheme for complicated
delivery care (nearmiss cases) and compared with cost of treatment. METHODS:
Crosssectional study was conducted and interview with 372 discharged patients
with nearmiss (life threatening) cases in Banten province was done. Information
was also captured from hospital records, including charges for consultation fees
and other fees, drugs and supplies, and other expenses. Other variables were also
collected from hospital documents and a statistical model was developed to learn
factors affecting the cost. We combined information with additional data from
other districts to obtain information on hospital’s perspective, how they accept the
scheme for provider payment. RESULTS: Subsidy for the poor has been started
since 2004 and provider payment scheme has been improving to respond the need
of quality services with adequate funding. Hospital type C (4 specialists only), how-
ever, is not happywith payment underDRG systemand itwas found that claims for
nearmiss cases were below its costs. Medical staffs were unhappy with incentive
systems and proposing ‘free delivery’ for all type of nearmiss cases would add
burden for the hospitals. Cost of treatment was ranging from USD 172 to USD 272.
Costs of drugs and supply constituted themajor proportion (20% - 48%) varies with
severity. Private hospital suggested that payment is too low and they are not inter-
ested in joining the scheme for the poor. Statistical analysis showed that severe
cases increased cost of treatment. Hospital claimed that the expected cost recovery
was still not achieved. CONCLUSIONS: Provider payment scheme was not well
accepted for severe cases since it was found below the cost. Realistic cost estimates
is expected to be assessed andmore fair scheme to any type of hospital is expected
to undertake.
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COST-EFFECTIVENESS OF ROTAVIRUS IMMUNIZATION IN VIETNAM:
EXPLORING IMPACTS OF HERD IMMUNITY AND PATTERNS OF
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